Moderna, Inc. $MRNA Shares Newly Acquired by True Freedom Investing LLC

Key Points

• True Freedom Investing LLC acquired 6,080 Moderna shares worth approximately $1.17 million in the third quarter. Institutional investors collectively own 75.33% of the company.
• Analysts maintain a consensus “Hold” rating, with six Buy, 15 Hold, and four Sell ratings and an average price target of $107.10.
• Moderna insiders sold 197,251 shares valued at approximately $33.9 million over the past three months, including sales by President Stephen Hoge and insider Shannon Klinger under pre-arranged trading plans.

True Freedom Investing LLC bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 6,080 shares of the company's stock, valued at approximately $1,171,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRNA. Physician Wealth Advisors Inc. increased its stake in Moderna by 8.3% in the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company's stock worth $171,000 after purchasing an additional 68 shares during the period. Fortitude Family Office LLC grew its holdings in shares of Moderna by 53.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company's stock worth $43,000 after purchasing an additional 77 shares during the last quarter. TD Waterhouse Canada Inc. increased its stake in Moderna by 2.6% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company's stock worth $246,000 after buying an additional 85 shares during the period. SteelPeak Wealth LLC increased its stake in Moderna by 3.9% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company's stock worth $654,000 after buying an additional 127 shares during the period. Finally, Western Pacific Wealth Management LP bought a new stake in Moderna during the 3rd quarter valued at about $29,000. 75.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Bank of America raised their target price on shares of Moderna from $170.00 to $200.00 and gave the stock a "neutral" rating in a research report on Friday, October 9th. Brookline Capital Markets reissued a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Morgan Stanley raised their price objective on Moderna from $89.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 7th. The Goldman Sachs Group lifted their target price on Moderna from $120.00 to $137.00 and gave the company a "neutral" rating in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and issued a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average price target of $107.10.

Insider Activity

In other news, President Stephen Hoge sold 40,294 shares of the business's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the transaction, the president directly owned 1,525,858 shares of the company's stock, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company's stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Stock Performance

Shares of MRNA stock opened at $221.72 on Monday. The firm has a market cap of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.16. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $254.48. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company's 50 day moving average is $182.49 and its 200 day moving average is $86.52.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna's revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.13) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.